DNA plasmid HIV vaccine design, number of doses, participant gender, and body mass index affect T-cell responses across HIV vaccine clinical trials by Morgan C, Jin X, Yu X, De Rosa S, Kublin J, Metch B, Keefer M, NIAID H

Phase 2a safety and immunogenicity testing of DNA and recombinant modified vaccinia ankara virus vaccines expressing virus-like particles by Goepfert P, Elizaga M, Montefiori D, Hural J, DeRosa S, Tomaras G, Seaton K, Sato A, Ouedraogo L, Donastorg Y, Cardinali M, Lama J, Baden L, Keefer M, McElrath J, Kalams S, Robinson H

Cardiac Safety in Clinical Trials with Preventive HIV Vaccine Candidates Based on Modified Vaccinia Ankara (MVA) by Schmidt, C, Kochhar, S, Excler, J, Smith, C, McMichael, A, Hanke, T, Bwayo, J, Jaoko, W, Weber, J, Kaleebu, P, Peters, B, Pantaleo, G, Vardas, E, Vasan, S, Keefer, M, Ramanathan, V, Boyle, R, Fast, P

Multiple antibody specificities (gp41, V1V2, and V3) elicited in the phase II multiclade (A, B, C) HIV-1 DNA prime, rAd5 boost vaccine trial by Williams WB, Jones K, Krambrink A, Grove D, Liu P, Yates NL, Moody MA, Ferrari G, Pollara J, Moodie Z, Morgan CA, Liao H, Montefiori DC, Ochsenbauer C, Kappes J, Hammer S, Mascola J, Koup R, Corey L, Nabel G, Gilbert P, Churchyard G, Keefer M, Graham BS, Haynes BF, Tomaras GD